(Circulation. 2000;102:157.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial
From the Maryland Medical Research Institute, Baltimore (G.L.K., S.A.F., M.L.T.); Clinical Trials Group (Y.R.) and Office of Biostatistics Research (N.L.G.), NHLBI, Bethesda, Md; Montreal Heart Institute, Montreal, Quebec, Canada (L.C.); Heart Disease Prevention Clinic (D.B.H.) and Angiogram Reading Center (C.W.), University of Minnesota, and Minneapolis Heart Institute (F.L.G.), Minneapolis; Cedars-Sinai Medical Center, Los Angeles, Calif (J.S.F., A.H.); Baylor College of Medicine, Houston, Tex (J.A.H.); and Cleveland Clinic Foundation, Cleveland, Ohio (B.J.H.).
Background—The Post Coronary Artery Bypass Graft Trial, designed to compare the effects of 2 lipid-lowering regimens and low-dose anticoagulation versus placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surgery, demonstrated that aggressive lowering of LDL cholesterol (LDL-C) levels to <100 mg/dL compared with a moderate reduction to 132 to 136 mg/dL decreased the progression of atherosclerosis in grafts. Low-dose anticoagulation did not significantly affect progression.
Methods and Results—Approximately 3 years after the last trial visit, Clinical Center Coordinators contacted each patient by telephone to ascertain the occurrence of cardiovascular events and procedures. The National Death Index was used to ascertain vital status for patients who could not be contacted. Vital status was established for all but 3 of 1351 patients. Information on nonfatal events was available for 95% of surviving patients. A 30% reduction in revascularization procedures and 24% reduction in a composite clinical end point were observed in patients assigned to aggressive strategy compared with patients assigned to moderate strategy during 7.5 years of follow-up, P=0. 0006 and 0.001, respectively. Reductions of 35% in deaths and 31% in deaths or myocardial infarctions with low-dose anticoagulation compared with placebo were also observed, P=0.008 and 0.003, respectively.
Conclusions—The long-term clinical benefit observed during extended follow-up in patients assigned to the aggressive strategy is consistent with the angiographic findings of delayed atherosclerosis progression in grafts observed during the trial. The apparent long-term benefit of low-dose warfarin remains unexplained.
Key Words: bypass • grafting • anticoagulation • lipids • follow-up studies
This article has been cited by other articles:
 |
|
 |
|
  Y. J. Hong, G. S. Mintz, S. W. Kim, S. Y. Lee, S. Y. Kim, T. Okabe, A. D. Pichard, L. F. Satler, R. Waksman, K. M. Kent, et al. Disease progression in nonintervened saphenous vein graft segments a serial intravascular ultrasound analysis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kulik, M. A. Brookhart, R. Levin, M. Ruel, D. H. Solomon, and N. K. Choudhry Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery Circulation, October 28, 2008; 118(18): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Wee, S. Girotra, A. R. Weinstein, M. A. Mittleman, and K. J. Mukamal The Relationship Between Obesity and Atherosclerotic Progression and Prognosis Among Patients With Coronary Artery Bypass Grafts: The Effect of Aggressive Statin Therapy J. Am. Coll. Cardiol., August 19, 2008; 52(8): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Liakopoulos, Y.-H. Choi, P. L. Haldenwang, J. Strauch, T. Wittwer, H. Dorge, C. Stamm, G. Wassmer, and T. Wahlers Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients Eur. Heart J., June 2, 2008; 29(12): 1548 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Shah, D. D. Waters, P. Barter, J. J.P. Kastelein, J. Shepherd, N. K. Wenger, D. A. DeMicco, A. Breazna, and J. C. LaRosa Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1938 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J.W. Wallitt, M. Jevon, and P. I. Hornick Therapeutics of Vein Graft Intimal Hyperplasia: 100 Years On Ann. Thorac. Surg., July 1, 2007; 84(1): 317 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
A. Goyal, J. H. Alexander, G. E. Hafley, S. H. Graham, R. H. Mehta, M. J. Mack, R. K. Wolf, L. H. Cohn, N. T. Kouchoukos, R. A. Harrington, et al. Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery Ann. Thorac. Surg., March 1, 2007; 83(3): 993 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) Circulation, December 19, 2006; 114(25): 2850 - 2870. [Full Text] [PDF]
|
|
|
|
|
|
V. Aboyans, L. Labrousse, P. Lacroix, J. Guilloux, S. Sekkal, A. Le Guyader, E. Cornu, and M. Laskar Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schmermund, S. Achenbach, T. Budde, Y. Buziashvili, A. Forster, G. Friedrich, M. Henein, G. Kerkhoff, F. Knollmann, V. Kukharchuk, et al. Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months: A Multicenter, Randomized, Double-Blind Trial Circulation, January 24, 2006; 113(3): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Pascual, J. M. Arribas, P. L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas, and M. Valdes Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery Ann. Thorac. Surg., January 1, 2006; 81(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 PREVENT IV Investigators Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial JAMA, November 16, 2005; 294(19): 2446 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fletcher, K. Berra, P. Ades, L. T. Braun, L. E. Burke, J. L. Durstine, J. M. Fair, G. F. Fletcher, D. Goff, L. L. Hayman, et al. Managing Abnormal Blood Lipids: A Collaborative Approach Circulation, November 15, 2005; 112(20): 3184 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okrainec, R. Platt, L. Pilote, and M. J. Eisenberg Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: A review of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goldman, K. Zadina, T. Moritz, T. Ovitt, G. Sethi, J. G. Copeland, L. Thottapurathu, B. Krasnicka, N. Ellis, R. J. Anderson, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: Results from a Department of Veterans Affairs Cooperative Study J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2149 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Spratt Reducing the Risk of Coronary Heart Disease via Lipid Reduction J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 9S - 13S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Fox, B. J. Hoogwerf, S. Czajkowski, R. Lindquist, G. Dupuis, J. A. Herd, L. Campeau, A. Hickey, F. B. Barton, and M. L. Terrin Quality of Life After Coronary Artery Bypass Graft: Results From the POST CABG Trial Chest, August 1, 2004; 126(2): 487 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herlitz, J. Holm, M. Peterson, B. W Karlson, M. Haglid Evander, L. Erhardt, and for the LoWASA study group Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA Study Eur. Heart J., February 1, 2004; 25(3): 232 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Werba, E. Tremoli, P. Massironi, M. Camera, A. Cannata, F. Alamanni, P. Biglioli, and A. Parolari Statins in coronary bypass surgery: rationale and clinical use Ann. Thorac. Surg., December 1, 2003; 76(6): 2132 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, F. D. Ferdinand, D. Galusha, S. S. Rathore, F. A. Masoudi, E. P. Havranek, D. Nilasena, M. J. Radford, and H. M. Krumholz Patterns of Secondary Prevention in Older Patients Undergoing Coronary Artery Bypass Grafting During Hospitalization for Acute Myocardial Infarction Circulation, September 9, 2003; 108(90101): II-24 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hackam Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy? Can. Med. Assoc. J., June 24, 2003; 168(13): 1689 - 1689. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Rudnicka, D. Ashby, P. Brennan, and T. Meade Thrombosis Prevention Trial: Compliance With Warfarin Treatment and Investigation of a Retained Effect Arch Intern Med, June 23, 2003; 163(12): 1454 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.L van Brussel, A.A Voors, J.M.P.G Ernst, P.J Knaepen, and H.W.M Plokker Venous coronary artery bypass surgery: a more than 20-year follow-up study Eur. Heart J., May 2, 2003; 24(10): 927 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Wright, J. G. Murphy, K. Bybee, and S. L. Kopecky Determining Optimal Statin Dosage-Reply-I Mayo Clin. Proc., March 1, 2003; 78(3): 381 - 381. [PDF]
|
|
|
|
 |
|
 A. T Hirsch and A. M Gotto Jr Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction Vascular Medicine, November 1, 2002; 7(4): 323 - 331. [Abstract] [PDF]
|
|
|
|
|
|
S. H. Rahimtoola Bilateral internal mammary artery grafting for coronary artery bypass grafting: why men versus women? Ann. Thorac. Surg., November 1, 2002; 74(5): 1435 - 1437. [Full Text] [PDF]
|
|
|
|
|
|
W. B. Applegate Elderly Patients' Adherence to Statin Therapy JAMA, July 24, 2002; 288(4): 495 - 497. [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413. [Full Text]
|
|
|
|
|
|
A. C. Yeung and P. Tsao Statin Therapy: Beyond Cholesterol Lowering and Antiinflammatory Effects Circulation, June 25, 2002; 105(25): 2937 - 2938. [Full Text] [PDF]
|
|
|
|
|
|
C. Knottenbelt, P. J. Brennan, T. W. Meade, and for the Medical Research Council's General Practic Antithrombotic Treatment and the Incidence of Angina Pectoris Arch Intern Med, April 22, 2002; 162(8): 881 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Arenillas, C. A. Molina, J. Montaner, S. Abilleira, M. A. Gonzalez-Sanchez;, and J. Alvarez-Sabin Progression and Clinical Recurrence of Symptomatic Middle Cerebral Artery Stenosis: A Long-Term Follow-Up Transcranial Doppler Ultrasound Study Stroke, December 1, 2001; 32(12): 2898 - 2904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Waters and P. Y. Hsue Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease: Treating Between the Lines Circulation, November 27, 2001; 104(22): 2635 - 2637. [Full Text] [PDF]
|
|
|
|
|
|
C. W. White, F. L. Gobel, L. Campeau, G. L. Knatterud, S. A. Forman, J. S. Forrester, N. L. Geller, J. A. Herd, A. Hickey, B. J. Hoogwerf, et al. Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial Circulation, November 27, 2001; 104(22): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Meade Cardiovascular disease--linking pathology and epidemiology Int. J. Epidemiol., October 1, 2001; 30(5): 1179 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Huynh, P. Theroux, P. Bogaty, J. Nasmith, and S. Solymoss Aspirin, Warfarin, or the Combination for Secondary Prevention of Coronary Events in Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Surgery Circulation, June 26, 2001; 103(25): 3069 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Ito, G. M. Delucca, and M. A. Aldridge The Relationship Between Low-Density Lipoprotein Cholesterol Goal Attainment and Prevention of Coronary Heart Disease-Related Events Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 129 - 135. [Abstract] [PDF]
|
|
|
|
|
|
G. G. Schwartz, A. G. Olsson, M. D. Ezekowitz, P. Ganz, M. F. Oliver, D. Waters, A. Zeiher, B. R. Chaitman, S. Leslie, T. Stern, et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial JAMA, April 4, 2001; 285(13): 1711 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Aronow Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 138M - 145. [Abstract] [Full Text]
|
|
|
|
 |
|
 Long-Term Benefit of Aggressive LDL Lowering and Anticoagulation After CABG Journal Watch Cardiology, October 27, 2000; 2000(1027): 6 - 6. [Full Text]
|
|
|
|
 |
|
 T. A. Jacobson "The Lower the Better" in Hypercholesterolemia Therapy: A Reliable Clinical Guideline? Ann Intern Med, October 3, 2000; 133(7): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Outcomes Data Support Aggressive LDL Lowering, Anticoagulation After CABG Journal Watch (General), July 25, 2000; 2000(725): 1 - 1. [Full Text]
|
|
|
|
|
|
D. D. Waters and R. R. Azar Postscripts From the Post Coronary Artery Bypass Graft Trial : The Sustained Benefit of More Aggressive Cholesterol Lowering and the Enigma of Low-Dose Anticoagulation Circulation, July 11, 2000; 102(2): 144 - 146. [Full Text] [PDF]
|
|
|
|
|
|
PREVENT IV Investigators Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial JAMA, November 16, 2005; 294(19): 2446 - 2454. [Abstract] [Full Text] [PDF]
|
|